{"entity":{"id":"nct07265674","kind":"trial","name":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer","aka":[],"tldr":"A phase 3 trial of Nanvuranlat in biliary tract cancer, run by J-Pharma Co., Ltd., now recruiting.","summary":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer is a phase 3 interventional study registered as NCT07265674 by J-Pharma Co., Ltd., with 480 participants planned, started 2026-05-11 and due to reach its primary completion in 2027-10. Interventions recorded: Nanvuranlat.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07265674","url":"https://clinicaltrials.gov/study/NCT07265674"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07265674","phase":"3","setting":"A Phase 3, Multicenter, Randomized, Open-label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients With Previously Treated Advanced Biliary Tract Cancer","sponsor":"J-Pharma Co., Ltd.","enrolled":480,"outcomes":[]},"route":"/trials/nct07265674/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}]}}